AMNEAL PHARMACEUTICALS INC (AMRX) Stock Price, Forecast & Analysis

NASDAQ:AMRX • US03168L1052

14.82 USD
+0.19 (+1.3%)
At close: Feb 13, 2026
14.82 USD
0 (0%)
After Hours: 2/13/2026, 8:00:00 PM

AMRX Key Statistics, Chart & Performance

Key Statistics
Market Cap4.66B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Shares314.36M
Float156.23M
52 Week High15
52 Week Low6.68
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)0.75
PE19.76
Fwd PE15.51
Earnings (Next)02-27
IPO2009-11-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
AMRX short term performance overview.The bars show the price performance of AMRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

AMRX long term performance overview.The bars show the price performance of AMRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 200 400 600

The current stock price of AMRX is 14.82 USD. In the past month the price increased by 12.36%. In the past year, price increased by 91.72%.

AMNEAL PHARMACEUTICALS INC / AMRX Daily stock chart

AMRX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to AMRX. When comparing the yearly performance of all stocks, AMRX is one of the better performing stocks in the market, outperforming 93.9% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
AMRX Full Technical Analysis Report

AMRX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to AMRX. AMRX has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AMRX Full Fundamental Analysis Report

AMRX Financial Highlights

Over the last trailing twelve months AMRX reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 25% compared to the year before.


Industry RankSector Rank
PM (TTM) 0.2%
ROA 0.16%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%6.25%
Sales Q2Q%11.68%
EPS 1Y (TTM)25%
Revenue 1Y (TTM)16.73%
AMRX financials

AMRX Forecast & Estimates

11 analysts have analysed AMRX and the average price target is 14.79 USD. This implies a price decrease of -0.2% is expected in the next year compared to the current price of 14.82.

For the next year, analysts expect an EPS growth of 40.07% and a revenue growth 8.67% for AMRX


Analysts
Analysts81.82
Price Target14.79 (-0.2%)
EPS Next Y40.07%
Revenue Next Year8.67%
AMRX Analyst EstimatesAMRX Analyst Ratings

AMRX Ownership

Ownership
Inst Owners45.17%
Ins Owners46.29%
Short Float %4.34%
Short Ratio2.64
AMRX Ownership

AMRX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.99983.195B
JNJ JOHNSON & JOHNSON20.9586.544B
MRK MERCK & CO. INC.22.44301.342B
PFE PFIZER INC9.18156.812B
BMY BRISTOL-MYERS SQUIBB CO9.98123.651B
ZTS ZOETIS INC18.4455.813B
RPRX ROYALTY PHARMA PLC- CL A8.7126.086B
VTRS VIATRIS INC6.2318.163B
ELAN ELANCO ANIMAL HEALTH INC24.0412.486B
AXSM AXSOME THERAPEUTICS INC221.279.135B

About AMRX

Company Profile

AMRX logo image Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,100 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Company Info

AMNEAL PHARMACEUTICALS INC

400 Crossing Boulevard, 3rd Floor

Bridgewater NEW JERSEY 08807 US

CEO: Chirag Patel

Employees: 8100

AMRX Company Website

AMRX Investor Relations

Phone: 19089473120

AMNEAL PHARMACEUTICALS INC / AMRX FAQ

What does AMRX do?

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,100 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.


What is the current price of AMRX stock?

The current stock price of AMRX is 14.82 USD. The price increased by 1.3% in the last trading session.


Does AMNEAL PHARMACEUTICALS INC pay dividends?

AMRX does not pay a dividend.


How is the ChartMill rating for AMNEAL PHARMACEUTICALS INC?

AMRX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


How is the valuation of AMNEAL PHARMACEUTICALS INC (AMRX) based on its PE ratio?

The PE ratio for AMNEAL PHARMACEUTICALS INC (AMRX) is 19.76. This is based on the reported non-GAAP earnings per share of 0.75 and the current share price of 14.82 USD.


Can you provide the number of employees for AMNEAL PHARMACEUTICALS INC?

AMNEAL PHARMACEUTICALS INC (AMRX) currently has 8100 employees.


Can you provide the short interest for AMRX stock?

The outstanding short interest for AMNEAL PHARMACEUTICALS INC (AMRX) is 4.34% of its float.